Clinical endpoint sensitivity in rheumatoid arthritis: modeling and simulation
- 809 Downloads
The commonly used efficacy endpoints in Rheumatoid Arthritis (RA) clinical trials are American College of Rheumatology 20 % improvement criteria (ACR20), ACR50, and ACR70 response rates, and the 28-joint disease activity score (DAS28). Longitudinal models to quantitate the exposure–response relationships for ACRs and DAS28 score were developed for four biologics used for the management of RA. The models were then used to simulate the clinical outcome at various time points following different treatment regimens. Discriminative sensitivity of these endpoints was assessed using a power analysis. The trial simulation and subsequent power analysis showed that both ACR20 and DAS28 exhibit much lower power in distinguishing between two doses investigated compared with distinguishing treatment effect over placebo/Methotrexate (MTX) control. ACR20 response rate is generally more powerful in detecting treatment effect over placebo/MTX control as compared to DAS28. The findings of current study provide useful information which will help future clinical trial design for the treatment of patients with RA.
KeywordsExposure–response Modeling and simulation Rheumatoid arthritis ACR20 ACR50 ACR70 DAS28 Sensitivity analysis
This research was supported by the Research Science Review (RSR) Funds at FDA.
The views expressed in this paper are those of the authors and do not necessarily represent those of the FDA.
- 3.Guidance for industry: Rheumatoid Arthritis: Developing Drug Products for Treatment (2013) Food and Drug Administration http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM354468.pdf. Accessed Jan 2014
- 6.van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39(1):34–40PubMedCrossRefGoogle Scholar